NCT06709521 - Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI) | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

February 12, 2025

Primary Completion Date

June 30, 2026

Study Completion Date

October 30, 2026

Conditions

Bacterial Infection

Interventions

DRUG

Iohexol

Iohexol,N,N´ -Bis(2,3-dihydroxypropyl)-5-\[N-(2,3-dihydroxypropyl)-acetamido\]-2,4,6-triiodoisophthalamide, is a non-ionic, water-soluble radiographic contrast medium with a molecular weight of 821.14 (iodine content 46.36%)

Trial Locations (10)

24014

RECRUITING

Carilion Roanoke Memorial Hospital, Roanoke

27710

RECRUITING

Duke University Hospital - Infectious Diseases, Durham

45267

RECRUITING

University of Cincinnati College of Medicine - Division of Infectious Diseases, Cincinnati

48073

RECRUITING

Corewell Health - Infectious Disease, Royal Oak

90505

RECRUITING

Torrance Memorial Medical Center, Torrance

90502-2006

RECRUITING

Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance

48202-2608

RECRUITING

Henry Ford Health System - Henry Ford Hospital, Detroit

27834-9997

RECRUITING

East Carolina University - Infectious Diseases and Tropical/Travel Medicine Clinic, Greenville

97239-3098

RECRUITING

Oregon Health and Science University - Adult Infectious Diseases Clinic, Portland

15213-3403

RECRUITING

University of Pittsburgh - Medicine - Infectious Diseases, Pittsburgh

All Listed Sponsors

lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH